Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?

Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer:... Breast Cancer Res Treat (2017) 165:467–468 DOI 10.1007/s10549-017-4351-0 LETTER TO THE EDITOR Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB? 1 1 1 • • • Vasileios Askoxylakis David P. Kodack Gino B. Ferraro Rakesh K. Jain Received: 27 May 2017 / Accepted: 19 June 2017 / Published online: 22 June 2017 Springer Science+Business Media, LLC 2017 We read with great interest the findings by Lewis-Phillips incidence of extracranial occurrence, whereas CNS relap- et al. on the preclinical delivery of trastuzumab in brain ses do not appear to be affected. Together, these data metastases [1]. The authors compared directly the uptake of suggest that trastuzumab does not directly cause BM, but radiolabeled trastuzumab in isogenic tumors implanted in fails to prevent recurrence in the brain. the brain or the mammary fat pad (MFP) of immune- The efficacy of trastuzumab against established BM competent mice. Interestingly, nearly equivalent Zr- appears to be limited, in comparison to its efficacy against trastuzumab uptake at both sites was reported. Efficacy extracranial disease. Although retrospective clinical anal- analysis of the murine analog of trastuzumab (muMab yses suggest that trastuzumab may prolong survival http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB?

Loading next page...
 
/lp/springer_journal/antibody-based-therapies-for-the-treatment-of-brain-metastases-from-122E1sbeZ0
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-017-4351-0
Publisher site
See Article on Publisher Site

Abstract

Breast Cancer Res Treat (2017) 165:467–468 DOI 10.1007/s10549-017-4351-0 LETTER TO THE EDITOR Antibody-based therapies for the treatment of brain metastases from HER2-positive breast cancer: time to rethink the importance of the BBB? 1 1 1 • • • Vasileios Askoxylakis David P. Kodack Gino B. Ferraro Rakesh K. Jain Received: 27 May 2017 / Accepted: 19 June 2017 / Published online: 22 June 2017 Springer Science+Business Media, LLC 2017 We read with great interest the findings by Lewis-Phillips incidence of extracranial occurrence, whereas CNS relap- et al. on the preclinical delivery of trastuzumab in brain ses do not appear to be affected. Together, these data metastases [1]. The authors compared directly the uptake of suggest that trastuzumab does not directly cause BM, but radiolabeled trastuzumab in isogenic tumors implanted in fails to prevent recurrence in the brain. the brain or the mammary fat pad (MFP) of immune- The efficacy of trastuzumab against established BM competent mice. Interestingly, nearly equivalent Zr- appears to be limited, in comparison to its efficacy against trastuzumab uptake at both sites was reported. Efficacy extracranial disease. Although retrospective clinical anal- analysis of the murine analog of trastuzumab (muMab yses suggest that trastuzumab may prolong survival

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Jun 22, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off